Loading stock data…
Vir Biotechnology, Inc. (VIR)
$11.18-0.20 (-1.80%)
Market ClosedLast close Sep 8
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vir Biotechnology, Inc. in the Healthcare sector is trading at $11.18 with a market capitalization of $1.9B. Wall Street consensus targets $20.78 (9 analysts), implying a +85.8% move over the next 12 months. The stock is currently near its 52-week high of $11.94, remaining 29.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +85.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | -$41,000↓ | $63.76M↑ | -$65,000↓ | $1.03M↓ | $1.79M |
| Gross Profit | — | $63.73M↑ | -$54,000↓ | $1.02M↓ | $1.79M |
| Operating Income | -$132.29M↓ | -$47.92M↑ | -$173.44M↓ | -$118.59M↑ | -$139.56M |
| Net Income | -$125.69M↓ | -$42.92M↑ | -$163.14M↓ | -$110.96M↑ | -$120.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.62%
Volume
Today's trading volume
1.61M
Recent News
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
HDV combination therapy achieved 88% viral clearance, advancing toward Phase 3 readouts.
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary
Moby summary of Vir Biotechnology, Inc.'s Q2 2026 earnings call
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer ca
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ...
Vir Biotechnology Inc (VIR) reports best-in-class HDV data, completes ECLIPSE enrollment, and extends cash runway into 2028.
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?